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Abstract
Background: Evidence-based mailed educational brochures about the harms of sedative-hypnotic use lead to
discontinuation of chronic benzodiazepine use in older adults. It remains unknown whether patients with mild
cognitive impairment (MCI) are able to understand the information in the EMPOWER brochures, and whether they
achieve similar rates of benzodiazepine discontinuation.
Methods: Post-hoc analysis of the EMPOWER randomized, double-blind, wait-list controlled trial that assessed the
effect of a direct-to-consumer educational intervention on benzodiazepine discontinuation. 303 community-dwelling
chronic users of benzodiazepine medication aged 65–95 years were recruited from general community pharmacies in
the original trial, 261 (86%) of which completed the trial extension phase. All participants of the control arm received
the EMPOWER brochure during the trial extension. Normal cognition (n = 139) or MCI (n = 122) was determined during
baseline cognitive testing using the Montreal Cognitive Assessment questionnaire. Changes in knowledge pre- and
post-intervention were assessed with a knowledge questionnaire and changes in beliefs were calculated using the
Beliefs about Medicines Questionnaire. Logistic regression was used to compare knowledge gained, change in beliefs
and benzodiazepine cessation rates between participants with and without MCI.
Results: Complete discontinuation of benzodiazepines was achieved in 39 (32.0% [24.4,40.7]) participants with MCI and
in 53 (38.1% [30.5,46.4]) with normal cognition (adjusted OR 0.79, 95% CI [0.45–1.38]). Compared to individuals with
normal cognition, MCI had no effect on the acquisition of new knowledge, change in beliefs about benzodiazepines or
elicitation of cognitive dissonance.
Conclusions: The EMPOWER brochure is effective for reducing benzodiazepines in community-dwelling older adults
with mild cognitive impairment.
Trial registration: Our ClinicalTrials.gov identifier is NCT01148186, June 21st 2010.
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Background
Sedative-hypnotic use is associated with cognitive im-
pairment, and may contribute to mild neurocognitive
disorders in older adults [1–3]. For this reason, both
long and short-acting benzodiazepines are listed in the
2015 Beers criteria of medications to avoid in older
adults [3]. A mild neurocognitive disorder is defined in
the DSM-5 as a noticeable decrement in cognitive func-
tion beyond that of normal aging, which requires indi-
viduals to engage in compensatory strategies to maintain
independence [4]. The term is meant to replace the pre-
viously used diagnosis of mild cognitive impairment
(MCI). Over 1-in-5 community dwelling older adults
have MCI at any given time, although the exact preva-
lence is difficult to estimate due to the variability in the
criteria used, the source of subjects, the fluctuating na-
ture of the condition and the reference standards [5, 6].
Individuals with MCI may demonstrate significant im-
pairments in their ability to understand, reason and
participate in health related decisions [7]. Longitudinal
data suggest that medical decision-making capacity in
patients with MCI tends to decline over time [8].
The majority of long-term benzodiazepine users aged
65 years of age and older report not being concerned
about side effects, mainly because they have never been
alerted to the risks [9]. However, when provided with
evidence-based information about harm in the form of a
mailed educational brochure, 27% of chronic users
discontinued benzodiazepines within 6 months in the
EMPOWER trial [10]. It remains unknown whether pa-
tients with MCI retain capacity to understand the mater-
ial in the brochure, and whether they respond equally
well to the educational intervention. The objective of
this report is to examine whether cognitive status
affected the comprehension and success rates of the
EMPOWER patient-centered educational approach to
the deprescribing of benzodiazepines.
Design & methods
Study population
Participants in the EMPOWER trial were adults aged
65 years and older with polypharmacy (≥5 medications),
taking at least one chronic benzodiazepine prescription
(≥3 months). Participants with self-reported epilepsy, a
diagnosis of established dementia, or a mental health
disorder requiring treatment with antipsychotic medica-
tion, were deemed ineligible. In order to exclude patients
with undiagnosed dementia from the study, the
Montreal Cognitive Assessment (MoCA) was adminis-
tered at an in-home baseline screening interview. The
MoCA was chosen due to its high sensitivity and specifi-
city for distinguishing normal individuals from those
with MCI [11]. Participants with a MoCA score of 26
and over were qualified as having normal cognition,
while those with scores of 21 to 25 were classified as
having mild cognitive impairment (MCI) [11]. Partici-
pants with scores under 21 were excluded in order to
eliminate all potential cases of dementia [11]. In the ori-
ginal EMPOWER trial, participants randomized to the
control group were wait-listed to receive the EMPOWER
brochure at the end of the 6-month study period. In an
extension to the trial, participants in the control arm
were followed for an additional 6 months after study
completion in order to evaluate their response to the
EMPOWER brochure. This paper analyses all EMPOWER
participants (from the intervention and control arm)
having received the EMPOWER brochure and having
completed the post-intervention EMPOWER assessment
by 1-year (n = 261) [10].
Intervention
The EMPOWER brochure consists of an 8-page paper-
based benzodiazepine deprescribing tool embedded with
program theories which participants received by mail.
Development of the intervention has previously been
described in detail [10, 12]. A generic version of the
EMPOWER tool is available at http://www.criugm.qc.ca/
fichier/pdf/BENZOeng.pdf. The deprescribing tool was
individualized with the name of the participant’s benzo-
diazepine on the front page. It included true and false
questions about the harms of benzodiazepines, a short
paragraph describing changes in drug metabolism with
age, suggestions for alternate non-drug therapies for
anxiety and insomnia, a peer champion story, and a
standard 21-week tapering protocol showing a picture-
based diminishing schedule of full-pill, half-pill, and
quarter-pill consumption. The pictogram was proposed
by consumers during the development of the interven-
tion and allows participants to apply the benzodiazepine
tapering protocol regardless of the type or dose of
sedative-hypnotic consumed.
Data collection
Baseline data, including demographic characteristics and
prescription details were recorded during the initial in-
person interview. Follow-up data was collected by phone
1 week, 6 weeks and 6 months after each participant
received the EMPOWER brochure by mail. Benzodi-
azepine cessation or dose reduction was ascertained
using pharmacy renewal profiles, which contained infor-
mation on drugs purchased, dates of purchase, dose, and
quantity served. Cessation was defined as an absence of
any benzodiazepine prescription renewal, sustained for a
minimum of 3 months during the follow-up period. A
significant dose reduction consisted of a >25% dose
reduction, sustained over a minimum of 3 months when
compared to baseline use. Withdrawal symptoms
were measured using the benzodiazepine withdrawal
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symptom questionnaire 6 weeks and 6 months post-
intervention. Participants reporting any withdrawal symp-
toms at either time point were qualified as having
experienced withdrawal symptoms [13].
Change in knowledge, beliefs and self-efficacy to taper
benzodiazepines
In order to evaluate whether MCI participants under-
stood and reacted similarly to the content of the depre-
scribing intervention, we measured knowledge gained,
change in beliefs, improvements in self-efficacy and fre-
quency of outreach to a healthcare professional. Change
was calculated by comparing responses on the pre and
post-intervention questionnaires. For knowledge, this
consisted of scores on four true or false questions [12].
Beliefs about the necessity of taking benzodiazepines
versus associated harms were measured by comparing
the total scores on the specific section of the beliefs
about medicines questionnaire [14]. Change in self-
efficacy was evaluated with the Medication Reduction
Self-efficacy scale [12]. Outreach to a healthcare profes-
sional was measured by self-report.
Analysis
Participant characteristics were described using means
with standard deviations for continuous data and per-
centages for categorical data. A chi-square test was used
when comparing baseline characteristics of MCI vs non-
MCI participants. Univariable logistic regression was
used to determine the odds of all reported outcomes
comparing participants with normal cognitive function
to those with MCI. Multivariate analyses were adjusted
for variables that were significantly associated with MCI
at baseline, namely living arrangement, education, base-
line self-efficacy and anxiety as an indication for therapy
(Table 1). The results are reported as proportions with
95% confidence intervals (CI), and odds ratios (OR) with
95% CI, as appropriate. By combining participants who
were randomized to the intervention, as well as the wait-
list control group who received the brochure during the
trial extension, the sample was powered to detect a 15%
difference in proportions of individuals with and without
MCI who discontinued benzodiazepines, based on an
alpha of 0.05 and 80% power. The statistical significance
for all analyses was set at p < 0.05 (two-sided). SPSS
Table 1 Participant characteristics at baseline by cognitive status
Characteristics All (N = 261) MCI (n = 122) Normal cognition (n = 139) p-value
Female, n (%) 187 (71.6) 90 (73.8) 97 (69.8) .494
Age years, Mean (SD) 74.4 (6.3) 75.3 (6.7) 73.7 (5.8) .08
Education – college or university degree, n (%) 67 (25.6) 21 (17.2) 46 (33.1) .003*
Living alone, n (%) 137 (52.4) 75 (61.5) 62 (44.6) .01*
MOCAb, Mean score (SD) 24.5 (2.4) 23.3 (1.4) 27.4 (1.3) .000*
General health status (poor or fair), n (%) 88 (32.8) 49 (32.8) 44 (31.7) .895
Comorbidities, Mean (SD) 7.4 (2.5) 7.2 (2.4) 7.6 (2.7) .335
Self-reported indication for benzodiazepine:
Insomniac, n (%) 159 (60.9) 73 (59.8) 86 (61.9) .417
Anxietyc, n (%) 126 (48.3) 70 (57.4) 56 (40.3) .006*
Duration of benzodiazepine use (years), Mean (SD) 10.7 (8.8) 10.3 (8.0) 10.9 (9.4) .548
Previous attempts at cessation, n (%) 119 (45.6) 52 (42.6) 67 (48.2) .321
Successful attempts, n (%) 41 (15.7) 14 (11.5) 27 (19.4) .123
Benzodiazepine typed, n (%):
Short-acting 70 (26.8) 36 (29.5) 34 (24.5) .358
Intermediate acting 180 (70.0) 81 (66.4) 99 (71.2) .400
Long acting 11 (4.2) 5 (4.1) 6 (4.3) .888
Benzodiazepine Equivalent dosea, Mean (SD) 1.24 (.85) 1.27 (.75) 1.25 (.82) .571
Number of medications at baseline 9.86 (3.7) 9.72 (3.8) 9.98 (3.6) .574
Baseline Self-efficacy in tapering benzodiazepine (/100), Mean (SD) 38.1 (35.6) 31.2 (34.8) 44.1 (35.4) .004*
*Level of significance, p < 0.05
aBenzodiazepine dose in mg of lorazepam equivalents/day
bMOCA: The Montreal Cognitive Assessment (scale 0–30)
cBased on medical diagnosis but self-reported by patients
dShort-acting = half-life <6 h, Intermediate acting = half-life 6–20 h, Long-acting = half-life >20 h
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Version 20.0 (SPSS Inc. Chicago, IL, USA) was used for
all analyses.
Results
Participants in the post-hoc analysis consisted of older
adults aged 74.4 years (6.3 year standard deviation)
(Table 1). Participants were taking an average of 10 dif-
ferent medications and reported a mean of 7 comorbidi-
ties, with almost one third classifying their health status
as unfavorable. The mean duration of benzodiazepine
use was 10.7 years, indicated for insomnia and/or
anxiety. Almost half (45.6%) of patients reported a previ-
ous attempt to taper their benzodiazepine. One third of
the latter (15.7%) succeeded in the attempt, prior to re-
initiating the drug at a later date.
One hundred twenty-two (46.7%) participants were
classified as having MCI at baseline. Participants with
MCI were less well educated, more likely to live alone,
more likely to be taking their benzodiazepine to treat
anxiety, and expressed a lower level of confidence for
successful tapering than their counterparts with normal
cognitive function (Table 1).
Complete discontinuation of benzodiazepines was
achieved in 92 participants, with 39 (32.0% [24.4,40.7])
meeting MOCA criteria for mild cognitive impairment
and 53 (38.1% [30.5,46.4]) having normal cognition
(Adjusted OR = 0.79, 95% CI 0.45 to 1.38). An additional
28 participants significantly reduced their benzodiazep-
ine dose during the same time period (12 in the normal
group and 16 MCI participants). In total, 65 (46.8%
[38.7–55.0]) participants with normal cognition and 55
(45.1% [36.5,53.9] MCI participants achieved dose reduc-
tion or complete discontinuation (Adjusted OR = 1.07,
95% CI 0.62 to 1.83) (Table 2).
Compared to participants with normal cognition,
those with MCI exhibited the same ability to acquire
new knowledge and change their beliefs following the
intervention. Self-efficacy to taper and experience of
withdrawal symptoms was the same in both groups.
Additionally, cognitive status did not affect the partici-
pants’ decision to partake in a discussion about the
intervention with their healthcare provider (Table 2).
Discussion
Although previous research indicates that individuals with
MCI perform significantly worse than controls in multiple
aspects of medical decision-making [7, 8, 15], we did not
detect any difference in response to the EMPOWER
deprescribing brochure among older adults who met
MOCA criteria for MCI. Participants with MCI demon-
strated improvements in knowledge and self-efficacy, were
able to change their beliefs about benzodiazepines, and
initiated discussions about deprescribing with a health
care provider. Clinicians should be encouraged to distrib-
ute the EMPOWER brochure to their MCI patients in
order to engage patients in conversations about depre-
scribing sedative hypnotics, leading to shared decision-
making despite declining cognitive status.
Strengths and limitations
This is the first study of its kind to explore the association
between MCI and the success rates of a patient-centered
educational deprescribing intervention in a community-
based clinical trial of older, community-dwelling adults.
As the mild neurocognitive disorder diagnosis was not yet
developed at the time of the study and the MoCA’s useful-
ness in detecting mild neurocognitive disorder is modest
[16], we categorized participants according to the older
Table 2 Outcomes of the EMPOWER intervention by cognitive status
Primary outcome All (n = 261)
(n, %)
MCI (n = 122)
(n, %)
Normal cognition





Cessation 92 (35.2) 39 (32.0) 53 (38.1) 0.76 [.46–1.27] .79 [.45–1.38]
Dose Reduction 28 (10.7) 16 (13.1) 12 (8.6) 1.60 [.72–3.53] 2.04 [.86–4.83]
Cessation + Dose Reduction 120 (45.9) 55 (45.1) 65 (46.8) .94 [.57–1.52] 1.07 [.62–1.83]
Process Outcomes
Improvement in knowledge 157 (60.2) 75 (61.5) 82 (59.0) 1.11 [.68–1.82] 1.06 [.62–1.80]
Change in beliefs 147 (56.3) 67 (54.9) 80 (57.6) .89 [.54–1.47] .84 [.48–1.43]
Improved self-efficacy
for tapering
144 (55.2) 68 (55.7) 76 (54.7) 1.04 [.64–1.70] .89 [.52–1.54]
Discussed intervention
with a physician
102 (39.1) 43 (35.2) 59 (42.6) .73 [.44–1.22] .75 [.43–1.32]
Discussed intervention
with a pharmacist
55 (21.1) 26 (21.3) 29 (20.8) 1.02 [.57–1.86] .89 [.46–1.72]
Experienced withdrawal
symptoms during cessation
31 (11.9) 12 (9.8) 19 (13.7) .69 [.32–1.49] .60 [.27–1.35]
aAnalyses adjusted for living arrangement, education, anxiety as an indication for benzodiazepine treatment and baseline self-efficacy
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MCI diagnosis. Our results are only generalizable to pa-
tients with mild-to-moderate MCI since we used a MoCA
cut-off score of 21, thus excluding the lower spectrum of
MCI (19–20), which overlaps with early dementia.
Additionally, as we did not re-measure scores on the
MOCA at study endpoint, and were unable to ascertain
whether cognition improved after discontinuation. The
mean lorazepam equivalent dose was only 1.25 mg/day in
both groups of participants, which may have facilitated
tapering.
Conclusions
This report illustrates that the EMPOWER brochure can
be distributed to community-dwelling older adults with
MCI and still work, whether directly through patient
comprehension of the material or through the support
of caregivers or family. The EMPOWER tool can and
should be used in primary care or memory clinics for
chronic benzodiazepine users who are candidates for
deprescribing sedative-hypnotic medication.
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